Clinical Development Clinical Trials Compound Screening Development 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .
Drug Discovery World
FEBRUARY 22, 2024
Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. The post Informatics helps virtual biotech bring compound to clinical trial appeared first on Drug Discovery World (DDW).
Expert insights. Personalized for you.
52 
Let's personalize your content